Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-20T00:38:35.952Z Has data issue: false hasContentIssue false

Delayed loss of residual hearing in Clarion® cochlear implant users

Published online by Cambridge University Press:  31 May 2006

M. Barbara
Affiliation:
Department of Clinical Neurology and Otorhinolaryngology, University of Rome ’La Sapienza’ II School of Medicine, Rome, Italy
A. Mattioni
Affiliation:
Department of Clinical Neurology and Otorhinolaryngology, University of Rome ’La Sapienza’ I School of Medicine, Rome, Italy.
S. Monini
Affiliation:
Department of Clinical Neurology and Otorhinolaryngology, University of Rome ’La Sapienza’ II School of Medicine, Rome, Italy
I. Chiappini
Affiliation:
Department of Clinical Neurology and Otorhinolaryngology, University of Rome ’La Sapienza’ I School of Medicine, Rome, Italy.
F. Ronchetti
Affiliation:
Department of Clinical Neurology and Otorhinolaryngology, University of Rome ’La Sapienza’ II School of Medicine, Rome, Italy
D. Ballantyne
Affiliation:
Department of Clinical Neurology and Otorhinolaryngology, University of Rome ’La Sapienza’ I School of Medicine, Rome, Italy.
P. Mancini
Affiliation:
Department of Clinical Neurology and Otorhinolaryngology, University of Rome ’La Sapienza’ I School of Medicine, Rome, Italy.
R. Filipo
Affiliation:
Department of Clinical Neurology and Otorhinolaryngology, University of Rome ’La Sapienza’ I School of Medicine, Rome, Italy.

Abstract

Hearing threshold has been measured in a group of patients following cochlear implantation with a Clarion® device for the last eight years. The patients had received either a pre-curved carrier or the Hi-Focus I plus Electrode Positioner System (EPS). The assessment was carried out within the first post-operative week as well as at a later stage, between six and 87 months, post-operatively. Residual hearing thresholds were still measurable early after surgery in 24.5 per cent of the patients, without differences between the two different Clarion® models. However, the number of subjects with measurable hearing dropped to 16.3 per cent as observed when hearing was measured at a later stage, with an equal distribution between the two groups of patients. From this study it has been possible to observe that only a limited number of patients maintain residual hearing after Clarion® cochlear implantation, and that this tends to decrease further over time. Nevertheless, the performance of these patients for speech tests did not appear to be affected by deterioration of the pure-tone auditory threshold.

Type
Research Article
Copyright
© Royal Society of Medicine Press Limited 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)